To better investigate the role of p53 as a determinant of sensitivity to adavosertib, we used a TP53 isogenic relapsed NALM6 B-ALL cell line model with wild type (TP53+/+), monoallelic knockout (TP53±), and biallelic knockout (TP53−/−) cells (Fig. 1B). This evidence concerns the gene TP53 and acute lymphoblastic leukemia.